ArticleJournal of neuromuscular diseases2025

Pilot study of canakinumab (Ilaris) in steroid naïve children with Duchenne muscular dystrophy demonstrates safety and exploratory changes in potential serum protein response biomarkers.

Christopher F Spurney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.